Advertisement
Among adults with one or more chronic conditions

Arthritis, Other Chronic Disease Takes Toll on Work Force

0
Arthritis + other chronic health conditions may keep up to one-third affected out of workplace
Most fibromyalgia drug therapy randomized controlled trials are funded by industry

Majority of Fibromyalgia Drug Trials Are Industry Sponsored

0
Almost two-thirds of trials had one or more authors with financial conflicts of interest
Nine states have enacted the Interstate Medical Licensure Compact law

Interstate Medical Licensure Compact Formed

0
Formation of compact commission triggered by enactment of law in seventh state: Alabama
Although most Medicare Part D plans cover at least one biologic disease-modifying antirheumatic drug

Most Part D Plans Cover at Least One Biologic DMARD

0
In most plans, patients required to pay coinsurance percentage, averaging 29.6 percent of drug costs
The prices hospitals charge patients for a number of common procedures rose more than 10 percent between 2011 and 2013

CMS: Hospital Charges for Common Procedures Up

0
And hematologists/oncologists and ophthalmologists top list of high earners
Issues related to rheumatoid arthritis

RA-Related Issues Impede Smoking Cessation

0
Smoking used as distraction from pain, coping mechanism for frustration of living with RA

May 2015 Briefing – Rheumatology

0
Here are what the editors at HealthDay consider to be the most important developments in Rheumatology for May 2015. This roundup includes the latest...
Low physician spending is contributing to an overall slowing of health care costs

AMA: Physicians Driving the Slowing of Health Care Costs

0
Physicians' spending grew more slowly over 2003 to 2013 than hospital and clinical spending
Too few women at high risk for osteoporosis are being tested for the condition

DXA Screening Found to Be Underused and Overused

0
Researchers find patients at highest risk for fractures often miss out on tests
Potential mechanisms for the antiatherosclerotic activity of methotrexate and adalimumab in rheumatoid arthritis have been identified

Antiatherosclerotic Activity ID’d for MTX, Adalimumab in RA

0
Activity may be mediated by effects on lipoprotein functions, macrophage metabolism